Popular Filters
Trials for PBC Patients
Selective PPAR-delta agonist
Seladelpar for Primary Biliary Cholangitis
Recruiting1 awardPhase 3
Lancaster, California
This trial is testing Seladelpar, a medication that may help people with a specific liver disease called Primary Biliary Cholangitis (PBC) and early-stage cirrhosis. The drug aims to reduce liver inflammation and damage, potentially improving liver health. Seladelpar has shown promising results in previous studies for PBC, despite initial safety concerns.
Elafibranor for Primary Biliary Cholangitis
Recruiting1 awardPhase 3
Tucson, Arizona
This trial is testing elafibranor, a medication for people with Primary Biliary Cholangitis (PBC) who do not respond to or cannot take the usual treatment. PBC is a liver disease that can lead to severe damage if untreated. Elafibranor aims to reduce harmful substances in the liver to prevent further damage. The study will also check if the medication is safe and helps with symptoms like itching and tiredness. Elafibranor is being tested as a new treatment option for PBC patients who do not respond to or cannot tolerate the standard treatments.
CNP-104 for Primary Biliary Cholangitis
Recruiting0 awardsPhase 1 & 2
Sacramento, California
This trial tests a new drug, CNP-104, in adults with a liver disease called primary biliary cholangitis. The drug is given through a vein to check its safety and effectiveness. The study will monitor patients for a period of time.
Trials for Primary Biliary Cholangitis Patients
Selective PPAR-delta agonist
Seladelpar for Primary Biliary Cholangitis
Recruiting1 awardPhase 3
Lancaster, California
This trial is testing Seladelpar, a medication that may help people with a specific liver disease called Primary Biliary Cholangitis (PBC) and early-stage cirrhosis. The drug aims to reduce liver inflammation and damage, potentially improving liver health. Seladelpar has shown promising results in previous studies for PBC, despite initial safety concerns.
CNP-104 for Primary Biliary Cholangitis
Recruiting0 awardsPhase 1 & 2
Sacramento, California
This trial tests a new drug, CNP-104, in adults with a liver disease called primary biliary cholangitis. The drug is given through a vein to check its safety and effectiveness. The study will monitor patients for a period of time.
Bile Acid Sequestrant
Volixibat for Primary Biliary Cholangitis
Recruiting0 awardsPhase 2
Miami, Florida
This trial is testing a medicine called volixibat that may help reduce itching in people with a liver disease that often causes severe itching. Volixibat works by blocking certain chemicals in the body that cause itching. The study also aims to see if the medicine can slow down the progression of the liver disease.
Phase 3 Trials
Selective PPAR-delta agonist
Seladelpar for Primary Biliary Cholangitis
Recruiting1 awardPhase 3
Lancaster, California
This trial is testing Seladelpar, a medication that may help people with a specific liver disease called Primary Biliary Cholangitis (PBC) and early-stage cirrhosis. The drug aims to reduce liver inflammation and damage, potentially improving liver health. Seladelpar has shown promising results in previous studies for PBC, despite initial safety concerns.
Elafibranor for Primary Biliary Cholangitis
Recruiting1 awardPhase 3
Tucson, Arizona
This trial is testing elafibranor, a medication for people with Primary Biliary Cholangitis (PBC) who do not respond to or cannot take the usual treatment. PBC is a liver disease that can lead to severe damage if untreated. Elafibranor aims to reduce harmful substances in the liver to prevent further damage. The study will also check if the medication is safe and helps with symptoms like itching and tiredness. Elafibranor is being tested as a new treatment option for PBC patients who do not respond to or cannot tolerate the standard treatments.
PPAR agonist
Elafibranor for Primary Biliary Cholangitis
Recruiting1 awardPhase 3
Chandler, Arizona
This trial is testing a drug called elafibranor on patients with Primary Biliary Cholangitis (PBC) who haven't responded to standard treatment. The goal is to see if elafibranor can lower a specific liver enzyme and improve symptoms. Initially, participants will receive different treatments, and later, all will receive elafibranor for an extended period. Elafibranor has shown promise in improving symptoms in previous trials.
Bile Acid Sequestrant
Linerixibat for Cholestasis
Recruiting2 awardsPhase 3
Sacramento, California
This trial is testing the safety and tolerability of the drug linerixibat in people with a condition called cholestatic pruritus, who have participated in other clinical trials for the same drug. All participants will receive linerixibat during the study, which is expected to last until the drug can be made available for general use. The total duration of the study will vary depending on when each participant joins and the availability of the drug in their country.
Trials With No Placebo
Bile Acid Sequestrant
Linerixibat for Cholestasis
Recruiting2 awardsPhase 3
Sacramento, California
This trial is testing the safety and tolerability of the drug linerixibat in people with a condition called cholestatic pruritus, who have participated in other clinical trials for the same drug. All participants will receive linerixibat during the study, which is expected to last until the drug can be made available for general use. The total duration of the study will vary depending on when each participant joins and the availability of the drug in their country.
Behavioral Intervention
Mind-Body Wellness Program for Primary Biliary Cirrhosis
Recruiting1 award2 criteria
Edmonton, Alberta
"This trial will test an online wellness program for women with Primary Biliary Cholangitis (PBC), a chronic liver disease that causes symptoms like fatigue, itching, and brain fog. The program includes
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.